Skip to main content

Table 1 Percentage of patients with adapted JIA ACR (aacr) response and inactive disease

From: PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis

CAN, N = 178
N(%) Aacr30 Aacr50 Aacr70 Aacr90 Aacr100 Inactive disease
Week 2 142 (80%) 125 (70%) 102 (57%) 65 (37%) 38 (21%) 36 (20%)
Week 12 125 (70%) 122 (69%) 108 (61%) 87 (49%) 54 (30%) 50 (28%)
  1. Data from missing patients not shown; aacr response = ACR response level plus absence of fever